Brief: Elevation Oncology Inc - Entering 2024 In Strong Financial Position, With Cash Into 2H 2025

Elevation Oncology

05/01/2024 14:01

Jan 5 (Reuters) - Elevation Oncology Inc  ELEV.O :
    * ENTERING 2024 IN STRONG FINANCIAL POSITION, WITH CASH INTO
2H
2025
    * UPDATE FROM ONGOING PHASE 1 CLINICAL TRIAL OF EO-3021 NOW
EXPECTED MID-2024
    * EXPANDING EO-3021 CLINICAL DEVELOPMENT PROGRAM TO INCLUDE
COMBINATION STRATEGY
    * ANNOUNCING HER3-TARGETING ADC AS SECOND PIPELINE PROGRAM;
DEVELOPMENT CANDIDATE NOMINATION IN 2024
    * EXPECTS CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AS
OF
SEPTEMBER 30, 2023 WILL BE SUFFICIENT TO FUND CURRENT OPERATIONS
INTO H2 2025

Source text for Eikon:  ID:nPn1j5pzNa 
Further company coverage:  ELEV.O 

 ((Reuters.Briefs@thomsonreuters.com;))